Early changes in clinical characteristics after emergency department therapy for acute heart failure syndromes: Identifying patients who do not respond to standard therapy

Heart Failure Reviews

Volumn 17, Issue 3, 2012, Pages 387-394

  Collins, Sean P ^a   Lindsell, Christopher J ^b   Storrow, Alan B ^a   Fermann, Gregory J ^b   Levy, Phillip D ^c   Pang, Peter S ^d   Weintraub, Neal ^b   Peacock, W Frank ^e   Sawyer, Douglas B ^a   Gheorghiade, Mihai ^d  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Clinical trials; Early enrollment; Heart failure

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; TROPONIN;

ACUTE HEART FAILURE; ACUTE HEART FAILURE SYNDROME; ADULT; AGED; ARTICLE; COHORT ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; RISK ASSESSMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; BLOOD PRESSURE; COHORT STUDIES; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME;

EID: 84862574142     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-011-9294-7     Document Type: Article

References (25)

1. VMAC Investigators (2002) Intravenous nesiritide vs. nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287:1531-1540
2. Collins SP, Hinckley WR, Storrow AB (2005) Critical review and recommendations for nesiritide use in the emergency department. J Emerg Med 29:317-329
3. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K (2005) Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 293:1900-1905
4. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Wilson WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365:32-43
5. Mebazaa A, Pang PS, Tavares M, Collins SP, Storrow AB, Laribi S, Andre S, Mark Courtney D, Hasa J, Spinar J, Masip J, Frank Peacock W, Sliwa K, Gayat E, Filippatos G, Cleland JG, Gheorghiade M (2010) The impact of early standard therapy on dyspnoea in patients with acute heart failure: the urgent-dyspnoea study. Eur Heart J 31:832-841
6. Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, Adams KF Jr (2007) Relation between dose of loop diuretics and outcomes in a heart failure population: results of the escape trial. Eur J Heart Fail 9:1064-1069
7. Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM (2002) The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 8:136-141
8. Weintraub NL, Collins SP, Pang PS, Levy PD, Anderson AS, Arslanian-Engoren C, Gibler WB, McCord JK, Parshall MB, Francis GS, GheorghiadeM (2010) Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the american heart association. Circulation 122:1975-1996
9. Collins SP, Levy PD, Lindsell CJ, Pang PS, Storrow AB, Miller CD, Naftilan AJ, Thohan V, Abraham WT, Hiestand B, Filippatos G, Diercks DB, Hollander J, Nowak R, Peacock WF, Gheorghiade M (2009) The rationale for an acute heart failure syndromes clinical trials network. J Card Fail 15:467-474
10. Storrow AB, Collins S, Lindsell CJ, Disalvo T, Han J, Weintraub NL (2007) Improving heart failure risk stratification in the ed: Stratify 1r01hl088459-01; treatment endpoints in acute decompensated heart failure 1k23hl085387-01a2
11. Teerlink JR, Metra M, Felker GM, Ponikowski P, Voors AA, Weatherley BD, Marmor A, Katz A, Grzybowski J, Unemori E, Teichman SL, Cotter G (2009) Relaxin for the treatment of patients with acute heart failure (pre-relax-ahf): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase iib study. Lancet 373:1429-1439
12. Levy P, Compton S, Welch R, Delgado G, Jennett A, Penugonda N, Dunne R, Zalenski R (2007) Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med 50:144-152
13. Peacock WFt, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH (2008) Cardiac troponin and outcome in acute heart failure. N Engl J Med 358:2117-2126
14. Voors AA, Davison BA, Felker GM, Ponikowski P, Unemori E, Cotter G, Teerlink JR, Greenberg BH, Filippatos G, Teichman SL, Metra M (2011) Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of pre-RELAX-AHF. Eur J Heart Fail 13:961-967
15. Aronson D, Burger AJ (2010) The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. J Card Fail 16:541-547
16. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC (2006) Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296:2217-2226
17. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ (2005) Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293:572-580
18. Apple FS (2009) A new season for cardiac troponin assays: It's time to keep a scorecard. Clin Chem 55:1303-1306
19. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH (2007) National academy of clinical biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 115:E 356-E 375
20. Morrow DA, de Lemos JA (2007) Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115:949-952
21. Gheorghiade M, Braunwald E (2011) A proposed model for initial assessment and management of acute heart failure syndromes. JAMA 305:1702-1703
22. Collins SP, Pang PS, Lindsell CJ, Kyriacou DN, Storrow AB, Hollander JE, Kirk JD, Miller CD, Nowak R, Peacock WF, Tavares M, Mebazaa A, Gheorghiade M. (2010) International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. Eur J Heart Fail 12: 1253-1260
23. Berry DA (2006) Bayesian clinical trials. Nat Rev Drug Discov 5:27-36
24. Potluri S, Ventura HO, Mulumudi M, Mehra MR (2004) Cardiac troponin levels in heart failure. Cardiol Rev 12:21-25
25. WFt Peacock, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH, Investigators A, WFt Peacock, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AHB (2008) Cardiac troponin and outcome in acute heart failure. N Engl J Med 358:2117-2126